Amsterdam, the Netherlands, December 2, 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Xeltis, a private Swiss/Dutch regenerative medicine company developing a new generation of pulmonary valves and vascular grafts according to the principles of endogenous tissue regeneration. LSP expects that this technology will both lead to better care and be cost effective. A PDF version of Xeltis’ press release can be found here.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over USD 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
For more information, please contact:
Clemens van Blitterswijk, Partner LSP HEF
Tel: +31 20 664 5500